Literature DB >> 15808809

Diagnosis of primary aldosteronism: from screening to subtype differentiation.

Paolo Mulatero1, Robert G Dluhy, Gilberta Giacchetti, Marco Boscaro, Franco Veglio, Paul M Stewart.   

Abstract

Numerous studies conducted in recent years have reported an increase in the prevalence of primary aldosteronism (PA). This increase has arisen because of changes in our screening methods used to detect PA, notably the widespread use of the ratio of plasma aldosterone concentration to plasma renin activity. A positive screening result, however, is not diagnostic and requires a confirmatory test. Strategies for screening and confirmation of PA and the techniques to identify the two main subtypes of PA--aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH)--are particularly important because hypertension in APA can be cured by adrenalectomy, whereas individuals affected with BAH can receive targeted medical treatment with mineralocorticoid receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808809     DOI: 10.1016/j.tem.2005.02.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  23 in total

1.  Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Authors:  Yuto Yamazaki; Yasuhiro Nakamura; Kei Omata; Kazue Ise; Yuta Tezuka; Yoshikiyo Ono; Ryo Morimoto; Yukinaga Nozawa; Celso E Gomez-Sanchez; Scott A Tomlins; William E Rainey; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

2.  Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism.

Authors:  K Kamemura; N Wada; T Ichijo; Y Matsuda; Y Fujii; T Kai; T Fukuoka; R Sakamoto; A Ogo; T Suzuki; H Umakoshi; M Tsuiki; M Naruse
Journal:  J Hum Hypertens       Date:  2016-09-01       Impact factor: 3.012

3.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof
Journal:  Mol Cell Endocrinol       Date:  2016-10-25       Impact factor: 4.102

Review 4.  Diagnosis and treatment of primary aldosteronism.

Authors:  Gian Paolo D Rossi
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

5.  Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism.

Authors:  Evelyn Fischer; Felix Beuschlein; Martin Bidlingmaier; Martin Reincke
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

6.  Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.

Authors:  Christina Westerdahl; Anders Bergenfelz; Anders Isaksson; Christina Nerbrand; Stig Valdemarsson
Journal:  Scand J Prim Health Care       Date:  2011-03       Impact factor: 2.581

Review 7.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 8.  The metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Giovanni Federspil; Franco Veglio; Paolo Mulatero
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

9.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

10.  The aldosterone to renin ratio in the evaluation of patients with incidentally detected adrenal masses.

Authors:  M Tzanela; G Effraimidis; G Effremidis; D Vassiliadi; A Szabo; N Gavalas; A Valatsou; E Botoula; N C Thalassinos
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.